DRREDDYNSEDr. Reddy's Laboratories Limited· PharmaceuticalsLowNeutral
Announced Mon, 30 Jun · 16:38 IST

Dr. Reddy's Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 24, 2025

Board & Shareholder Meetings View source PDF

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Dr. Reddy's Laboratories has notified exchanges about its 41st AGM, to be held on July 24, 2025 at 11:00 AM IST via video conferencing. The agenda includes adopting the FY25 audited financial statements and declaring a final dividend of ₹8 per equity share (face value ₹1), with payment due on or before July 30, 2025. A key special business item is the re-appointment of G V Prasad as Co-Chairman and Managing Director for another 5-year term (January 30, 2026 to January 29, 2031), with his monthly salary rising from ₹12 lakh to ₹14.4 lakh and HRA from ₹6 lakh to ₹7.2 lakh, along with up to 0.75% of net profits as commission. The notice also seeks ratification of ₹9 lakh remuneration for Cost Auditors Sagar & Associates for FY26, and approval to appoint Makarand M. Joshi & Co. as Secretarial Auditors for a 5-year term starting April 1, 2025. E-voting runs from July 20 to July 23, with July 17 as the cut-off date.

Likely market impact

Shareholders stand to receive an ₹8 per share dividend if approved at the AGM, with the record date set as July 10, 2025. The proposed leadership continuity with a revised executive pay package (~85% variable and performance-linked) is broadly in line with peer benchmarks and unlikely to be controversial, making this a routine procedural filing with no major price-moving signal.